Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2006
Event: Entry into a Material Definitive Agreement for a public offering of debt securities.
Key Financial Metrics
This filing details a debt issuance rather than operational financial performance. The following debt metrics are disclosed:
- Total Debt Issued: $4,000,000,000 aggregate principal amount.
- 2009 Notes: $500,000,000 principal; 5.375% interest rate; due May 15, 2009.
- 2011 Notes: $1,500,000,000 principal; 5.600% interest rate; due May 15, 2011.
- 2016 Notes: $2,000,000,000 principal; 5.875% interest rate; due May 15, 2016.
- Underwriters: ABN AMRO Incorporated, Banc of America Securities LLC, J.P. Morgan Securities Inc., and Morgan Stanley & Co. Incorporated.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, or existing liquidity positions.
Material Changes
The material change reported is the execution of Underwriting and Pricing Agreements to issue the senior notes described above. This increases the company's outstanding debt obligations by $4 billion effective May 9, 2006.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the agreements but does not include specific management commentary on future outlook or strategic rationale beyond the transaction details.
Risks and Contingencies: The filing references the Registration Statement on Form S-3 (File No. 333-132104) filed on February 28, 2006, for details regarding the offering. No specific new risks or contingencies are detailed in this text excerpt.
Investor Verification Checklist
- Verify the final net proceeds received after underwriting discounts and expenses (not explicitly stated in this text).
- Review the Registration Statement on Form S-3 (File No. 333-132104) for the full prospectus and use of proceeds.
- Confirm the impact of the new $4 billion debt load on the company's leverage ratios and credit ratings.
- Check subsequent filings for the actual closing date and final pricing if different from the preliminary agreement.